Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEG-B-09
- Development stage
- Unknown
- Administration
- Oral
01
Overview
MEG-B-09 is a pharmaceutical product that has been studied under the combination name ABO/MEG-B-09 for use in children with acute cough. Its precise composition, mechanism of action, and pharmacological classification have not been explicitly detailed in the available literature or clinical trial records. It is described as a "syrup" formulation for pediatric use, but no molecular or chemical description is available from authoritative sources.
- Brand names
- MEG-B-09MEG-B09MEG-B 09
- Other names
- MEG-B-09MEG-B09MEG-B 09
Beyond the preview
Go deeper on MEG-B-09.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEG-B-09.